


## FTX-6746

<b>Cat. No.:</b>	HY-153364		
<b>CAS No.:</b>	2829349-96-2		
<b>Molecular Formula:</b>	C <sub>16</sub> H <sub>7</sub> ClF <sub>2</sub> N <sub>2</sub> O		
<b>Molecular Weight:</b>	316.69		
<b>Target:</b>	PPAR		
<b>Pathway:</b>	Cell Cycle/DNA Damage; Vitamin D Related/Nuclear Receptor		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



## SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 50 mg/mL (157.88 mM; ultrasonic and warming and heat to 80°C)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	3.1577 mL	15.7883 mL	31.5766 mL
		5 mM	0.6315 mL	3.1577 mL	6.3153 mL
10 mM		0.3158 mL	1.5788 mL	3.1577 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (7.89 mM); Clear solution; Need ultrasonic  2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (7.89 mM); Clear solution; Need ultrasonic				

## BIOLOGICAL ACTIVITY

<b>Description</b>	FTX-6746 is an orally active PPARG inhibitor. FTX-6746 shows potent tumor inhibition in mouse xenograft models <sup>[1]</sup> .	
<b>IC<sub>50</sub> &amp; Target</b>	PPAR $\gamma$	
<b>In Vivo</b>	FTX-6746 (3-60 mg/kg; po; twice daily for 21 d) results significant tumor suppression in UMUC9 or HT1197 xenograft model in mouse <sup>[1]</sup> .	
	MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
<b>Animal Model:</b>	UMUC9 or HT1197 xenograft model in NCG or Balb/C nude mice <sup>[1]</sup>	

---

Dosage:	3 mg/kg, 10 mg/kg, 30 mg/kg, 60 mg/kg
Administration:	PO; twice daily for 21 days
Result:	Resulted >100% tumor growth inhibition at day 21 in HT1197 xenograft model. Resulted up to 80% target gene suppression in tumor tissue at day 2.

---

## REFERENCES

---

[1]. Mertz J, et al. Novel inhibitors of the luminal lineage transcription factor peroxisome proliferator-activated receptor gamma (PPARG) durably eradicate tumors in urothelial cancer (UC) animal models[J]. European Journal of Cancer, 2022, 174: S33-S34.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA